
    
      Novartis will consider this study a success if, at one month following the second
      vaccination, the two-sided 95% CI of the ratio of the hSBA GMTs for each of 3 serogroup B
      reference strains (H44/76, 5/99, and NZ98/254) and the two-sided 95% CI of the ratio of the
      ELISA GMCs against vaccine antigen 287-953 are contained within the interval (0.5, 2.0).
    
  